Immunotherapy is a treatment that mobilizes the body’s own immune system to fight diseases. A new type of personalized immunotherapy — CAR T-cell therapy — is revolutionizing treatment for B-cell acute lymphoblastic leukemia (ALL), the most common pediatric cancer.

Most children with ALL can be cured using conventional treatments: chemotherapy, radiation and stem cell transplant. But in 20 percent of cases, the cancer is refractory (does not respond to treatment) or returns after treatment. Until now, doctors had few options to fight aggressive ALL. Today, the medical community sees great promise in CAR T-cell therapy for these patients.

CAR (Chimeric Antigen Receptor)T-cell therapy reprograms a patient’s disease-fighting white blood cells (T-cells) to seek out, recognize and attack cancer cells without harming healthy cells. After CAR T-cell immunotherapy saved the life of a young ALL patient in Philadelphia five years ago, the experimental treatment was offered to more children through clinical trials. In the majority of cases, signs of cancer disappeared and the patients continue to be in remission.

How Does CAR T-cell Therapy Work?

How Does CAR T-Cell Therapy Work?

CAR T-cell Therapy for Pediatric Patients

Comer Children's pediatric cancer experts talk about CAR T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia.